Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,070,000 shares, a decrease of 21.3% from the September 30th total of 1,360,000 shares. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily volume of 684,000 shares, the short-interest ratio is currently 1.6 days.
Atyr PHARMA Price Performance
Atyr PHARMA stock traded up $0.06 during mid-day trading on Monday, hitting $3.32. The company's stock had a trading volume of 2,312,168 shares, compared to its average volume of 557,782. Atyr PHARMA has a 52-week low of $1.08 and a 52-week high of $3.54. The firm has a market cap of $228.77 million, a P/E ratio of -3.67 and a beta of 1.21. The company has a current ratio of 7.63, a quick ratio of 7.63 and a debt-to-equity ratio of 0.01. The stock's 50 day moving average is $2.08.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. As a group, analysts forecast that Atyr PHARMA will post -0.91 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Wells Fargo & Company initiated coverage on Atyr PHARMA in a report on Friday, October 4th. They issued an "overweight" rating and a $17.00 target price on the stock. Jefferies Financial Group began coverage on Atyr PHARMA in a report on Thursday, September 5th. They set a "buy" rating and a $9.00 price objective on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $16.00 target price on shares of Atyr PHARMA in a report on Wednesday, August 14th. Finally, HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Thursday, August 15th.
View Our Latest Stock Analysis on Atyr PHARMA
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
Read More
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
